// Focus Areas
Where we focus, and why it matters.
We focus on disease areas where biology-first targeting, strong translational anchors, and the right modality can generate differentiated therapeutics.
Oncology [solid tumours]
Solid tumours remain one of the hardest settings in oncology due to antigen complexity, tumour microenvironment constraints, and immune evasion.
Our oncology programs are built to address these realities through modality selection, safety-by-design principles, and biomarker-driven translation.
Age-related disorders
Age-related disorders are driven by system-level changes that include immune ageing, chronic inflammation, and progressive tissue dysfunction.
We build programs that connect ageing-related disease mechanisms to actionable targets and measurable biomarkers, enabling pragmatic development paths.
Senescence-linked disease mechanisms
Cellular senescence can contribute to chronic inflammatory signalling and functional decline across tissues.
Our senescence program focuses on translating senescence-associated biology into development-ready programs with clear biomarker anchors and decision points.
What we measure
Biomarker signals that reflect mechanism engagement.
Patient stratification hypotheses when relevant.
Functional readouts linked to disease biology.
Decision points that reduce uncertainty across stages.